BioSpace News Archive

Study Affirms the Potential of NGTs to Significantly Contribute to Agriculture Sustainability, the Key Objectives of the European Green Deal (Farm to Fork), and Makes an Urgent Call for Regulatory Reform

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an expansion of the Moderna Technology Center in Norwood, MA including more than doubling of space to transform the facility from a production and lab space to an industrial technology center.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its first quarter 2021 financial results and provide a corporate update on Tuesday, May 11, 2021.

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission in patients with autoimmune (‘1805 a protein drug) and allergic disease (‘1104 a peptide drug), announced today positive data from a multiple ascending dose (MAD) Phase 1 clinical trial evaluating the safety and tolerability of ‘1104, a first-in-class peptide for the treatment of allergic disease

Evotec SE will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021.

From a cleaner freight train to an automated beehive, a way to recycle fabric, and other bold, new technologies, the 5th annual awards honor the products, concepts, companies, policies, and designs that are pursuing innovation for the good of society and the planet

Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab

More than 700 Reproductive Endocrinologists in the U.S. now access ReceptivaDx™, representing 80% of all fertility centers in the country; new international contracts signed.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management is scheduled to participate in the following upcoming virtual investor conferences:

New preclinical data show that LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern